YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study

Bibliographic Details
Main Author: Tan,You-Wen
Publication Date: 2012
Other Authors: Ge,Guo-Hong, Zhao,Wei, Gan,Jian-He, Zhao,Yun, Niu,Zhi-Lin, Zhang,Dong-Jun, Chen,Li, Yu,Xue- Jun, Yang,Li-Jun
Format: Article
Language: eng
Source: Brazilian Journal of Infectious Diseases
Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300006
Summary: OBJECTIVE: This study aimed to determine the natural prevalence of variants of tyrosine-methionine-aspartic acid-aspartic acid (YMDD) motif in patients with chronic hepatitis B (CHB), and to explore its relation with demographic and clinical features, hepatitis B virus (HBV) genotypes, and HBV DNA levels. METHODS: A total of 1,042 antiviral treatment naïve CHB patients (including with lamivudine [LAM]) in the past year were recruited from outpatient and inpatient departments of six centers from December 2008 to June 2010. YMDD variants were analyzed using the HBV drug resistance line probe assay (Inno-Lipa HBV-DR). HBV genotypes were detected with polymerase chain reaction (PCR) microcosmic nucleic acid cross-ELISA, and HBV deoxyribonucleic acid (DNA) was quantitated with real-time PCR. All serum samples underwent tests for HBV, HCV, and HDV with ELISA. RESULTS: YMDD variants were detected in 23.3% (243/1042) of CHB patients. YMDD mutation was accompanied by L180M mutation in 154 (76.9%) patients. Both wild-type HBV and YMDD variant HBV were present in 231 of 243 patients. Interestingly, 12 patients had only YIDD and/or YVDD variants without wild YMDD motif. In addition, 27.2% (98/359) of HbeAg-positive patients had YMDD mutations, which was higher than that in HbeAg-negative patients (21.2%, 145/683). The incidence of YMDD varied among patients with different HBV genotypes, but the difference was not significant. Moreover, the incidence of YMDD in patients with high HBV DNA level was significantly higher than that in those with low HBV DNA level. CONCLUSION: Mutation of YMDD motif was detectable at a high rate in CHB patients in this study. The incidence of YMDD may be correlated with HBeAg and HBV DNA level.
id BSID-1_d5016c3323d8ca8a986bcabf798a1154
oai_identifier_str oai:scielo:S1413-86702012000300006
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center studyYMDDmutationschronic hepatitis Banti-viral therapyOBJECTIVE: This study aimed to determine the natural prevalence of variants of tyrosine-methionine-aspartic acid-aspartic acid (YMDD) motif in patients with chronic hepatitis B (CHB), and to explore its relation with demographic and clinical features, hepatitis B virus (HBV) genotypes, and HBV DNA levels. METHODS: A total of 1,042 antiviral treatment naïve CHB patients (including with lamivudine [LAM]) in the past year were recruited from outpatient and inpatient departments of six centers from December 2008 to June 2010. YMDD variants were analyzed using the HBV drug resistance line probe assay (Inno-Lipa HBV-DR). HBV genotypes were detected with polymerase chain reaction (PCR) microcosmic nucleic acid cross-ELISA, and HBV deoxyribonucleic acid (DNA) was quantitated with real-time PCR. All serum samples underwent tests for HBV, HCV, and HDV with ELISA. RESULTS: YMDD variants were detected in 23.3% (243/1042) of CHB patients. YMDD mutation was accompanied by L180M mutation in 154 (76.9%) patients. Both wild-type HBV and YMDD variant HBV were present in 231 of 243 patients. Interestingly, 12 patients had only YIDD and/or YVDD variants without wild YMDD motif. In addition, 27.2% (98/359) of HbeAg-positive patients had YMDD mutations, which was higher than that in HbeAg-negative patients (21.2%, 145/683). The incidence of YMDD varied among patients with different HBV genotypes, but the difference was not significant. Moreover, the incidence of YMDD in patients with high HBV DNA level was significantly higher than that in those with low HBV DNA level. CONCLUSION: Mutation of YMDD motif was detectable at a high rate in CHB patients in this study. The incidence of YMDD may be correlated with HBeAg and HBV DNA level.Brazilian Society of Infectious Diseases2012-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300006Brazilian Journal of Infectious Diseases v.16 n.3 2012reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702012000300006info:eu-repo/semantics/openAccessTan,You-WenGe,Guo-HongZhao,WeiGan,Jian-HeZhao,YunNiu,Zhi-LinZhang,Dong-JunChen,LiYu,Xue- JunYang,Li-Juneng2012-06-20T00:00:00Zoai:scielo:S1413-86702012000300006Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2012-06-20T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
title YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
spellingShingle YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
Tan,You-Wen
YMDD
mutations
chronic hepatitis B
anti-viral therapy
title_short YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
title_full YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
title_fullStr YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
title_full_unstemmed YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
title_sort YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study
author Tan,You-Wen
author_facet Tan,You-Wen
Ge,Guo-Hong
Zhao,Wei
Gan,Jian-He
Zhao,Yun
Niu,Zhi-Lin
Zhang,Dong-Jun
Chen,Li
Yu,Xue- Jun
Yang,Li-Jun
author_role author
author2 Ge,Guo-Hong
Zhao,Wei
Gan,Jian-He
Zhao,Yun
Niu,Zhi-Lin
Zhang,Dong-Jun
Chen,Li
Yu,Xue- Jun
Yang,Li-Jun
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Tan,You-Wen
Ge,Guo-Hong
Zhao,Wei
Gan,Jian-He
Zhao,Yun
Niu,Zhi-Lin
Zhang,Dong-Jun
Chen,Li
Yu,Xue- Jun
Yang,Li-Jun
dc.subject.por.fl_str_mv YMDD
mutations
chronic hepatitis B
anti-viral therapy
topic YMDD
mutations
chronic hepatitis B
anti-viral therapy
description OBJECTIVE: This study aimed to determine the natural prevalence of variants of tyrosine-methionine-aspartic acid-aspartic acid (YMDD) motif in patients with chronic hepatitis B (CHB), and to explore its relation with demographic and clinical features, hepatitis B virus (HBV) genotypes, and HBV DNA levels. METHODS: A total of 1,042 antiviral treatment naïve CHB patients (including with lamivudine [LAM]) in the past year were recruited from outpatient and inpatient departments of six centers from December 2008 to June 2010. YMDD variants were analyzed using the HBV drug resistance line probe assay (Inno-Lipa HBV-DR). HBV genotypes were detected with polymerase chain reaction (PCR) microcosmic nucleic acid cross-ELISA, and HBV deoxyribonucleic acid (DNA) was quantitated with real-time PCR. All serum samples underwent tests for HBV, HCV, and HDV with ELISA. RESULTS: YMDD variants were detected in 23.3% (243/1042) of CHB patients. YMDD mutation was accompanied by L180M mutation in 154 (76.9%) patients. Both wild-type HBV and YMDD variant HBV were present in 231 of 243 patients. Interestingly, 12 patients had only YIDD and/or YVDD variants without wild YMDD motif. In addition, 27.2% (98/359) of HbeAg-positive patients had YMDD mutations, which was higher than that in HbeAg-negative patients (21.2%, 145/683). The incidence of YMDD varied among patients with different HBV genotypes, but the difference was not significant. Moreover, the incidence of YMDD in patients with high HBV DNA level was significantly higher than that in those with low HBV DNA level. CONCLUSION: Mutation of YMDD motif was detectable at a high rate in CHB patients in this study. The incidence of YMDD may be correlated with HBeAg and HBV DNA level.
publishDate 2012
dc.date.none.fl_str_mv 2012-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300006
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1413-86702012000300006
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.16 n.3 2012
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209242048364544